Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin in Pediatric Patients With EGFR-Positive Relapsed/Refractory or Metastatic Solid Tumors
NCT07584499Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), Lymphoepithelial carcinoma (LEC) and 7 more, sponsored by Sun Yat-sen University. Primary endpoint: Dose-limiting toxicities. Started May 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)Lymphoepithelial carcinoma (LEC)rhabdomyosarcoma (RMS)neuroblastoma
Beyond the preview
Go deeper on NCT07584499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584499.